Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
SABCS 2024
In light of WSG-ADAPT HR+/HER2– trial at SABCS 2024 showing a 5 year iDFS benefit with neoadjuvant nab-paclitaxel over paclitaxel, will you change your practice?
Related Questions
What are your top takeaways in Radiation Oncology from SABCS 2024?
What are your top takeaways in Medical Oncology from SABCS 2024?
Is there data supporting the extension of adjuvant olaparib beyond one year in patients with early-stage HER2-negative breast cancer and germline BRCA1/2 mutations?
In patients with ATM heterozygous mutation, do you prefer aromatase inhibitor over tamoxifen for adjuvant endocrine therapy?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Is there evidence supporting the use of nab-paclitaxel in place of paclitaxel in the KEYNOTE-522 neoadjuvant regimen for triple-negative breast cancer, in cases of paclitaxel hypersensitivity?
Considering the results of the I-SPY2 trial discussed at ASCO 2025, what would be your approach to treating a T1cN0 (tumor 1.5-1.9cm) young, fit patient? NACT THP x4 or surgery upfront?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
Would you add pertuzumab to adjuvant therapy for a premenopausal female with HR+, HER2+ IDC with N1mic disease?
